TY - JOUR
T1 - Peripheral Blood Mononuclear Cells' Proliferative Response to Human Parvovirus B19 Antigens in Patients with Rheumatoid Arthritis
AU - Bratslavska, Olga
AU - Kozireva, Svetlana
AU - Kadisa, Anda
AU - Svirskis, Simons
AU - Pavlova, Jeļena
AU - Lejnieks, Aivars
AU - Murovska, Modra
N1 - Autore J.Pavlova Scopus datubāzē pie raksta nav norādīta, bet žurnāla "Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences" PDF formāta publikācijā ir norādīta.
Publisher Copyright:
© 2016 by Svetlana Kozireva.
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - This study aimed to determine peripheral blood mononuclear cells' (PBMC) proliferative response to parvovirus B19 (B19) antigens in rheumatoid arthritis (RA) patients and possible changes in proliferative response due to chemotherapy. Serum and blood samples of 52 RA patients and 25 sex and age matched healthy individuals were examined for the presence of anti-B19 IgG and IgM class antibodies and virus specific DNA sequence by the recomLine B19 test and nested polymerase chain reaction, respectively. The PBMC proliferative activity was estimated on the 3rd and 6th day of PBMC cultivation in the presence of virus and B19 VP1/VP2 peptide, using thymidine incorporation assay. On the 3rd day, PBMC response to B19 antigens was detected in 74.1% RA patients with active, in 44.8%-with remote and in 40%-with latent stage of persistent B19 infection, while in the control group the response was observed only in two individuals with active viral infection. On the 6th day, the response was found in 50% RA patients with active, 68.9%-with remote and in 80%-with latent stage of latent persistent infection as well as in 41.1% remotely infected control individuals. The highest PBMC mean stimulation indices were detected in the RA patients and control persons with active infection as well as in RA patients with latent stage of persistent viral infection. On the 3rd and 6th day, strong proliferative response was significantly more frequently observed in RA patients not receiving methotrexate treatment, compared to the patients receiving methotrexate treatment in different combinations with other drugs. RA patients had more frequent and faster response to B19 antigens than apparently healthy persons.
AB - This study aimed to determine peripheral blood mononuclear cells' (PBMC) proliferative response to parvovirus B19 (B19) antigens in rheumatoid arthritis (RA) patients and possible changes in proliferative response due to chemotherapy. Serum and blood samples of 52 RA patients and 25 sex and age matched healthy individuals were examined for the presence of anti-B19 IgG and IgM class antibodies and virus specific DNA sequence by the recomLine B19 test and nested polymerase chain reaction, respectively. The PBMC proliferative activity was estimated on the 3rd and 6th day of PBMC cultivation in the presence of virus and B19 VP1/VP2 peptide, using thymidine incorporation assay. On the 3rd day, PBMC response to B19 antigens was detected in 74.1% RA patients with active, in 44.8%-with remote and in 40%-with latent stage of persistent B19 infection, while in the control group the response was observed only in two individuals with active viral infection. On the 6th day, the response was found in 50% RA patients with active, 68.9%-with remote and in 80%-with latent stage of latent persistent infection as well as in 41.1% remotely infected control individuals. The highest PBMC mean stimulation indices were detected in the RA patients and control persons with active infection as well as in RA patients with latent stage of persistent viral infection. On the 3rd and 6th day, strong proliferative response was significantly more frequently observed in RA patients not receiving methotrexate treatment, compared to the patients receiving methotrexate treatment in different combinations with other drugs. RA patients had more frequent and faster response to B19 antigens than apparently healthy persons.
KW - autoimmune disease
KW - B19 infection
KW - cellular response to VP1/VP2 B19 peptide
UR - http://www.scopus.com/inward/record.url?scp=84983395537&partnerID=8YFLogxK
U2 - 10.1515/prolas-2016-0023
DO - 10.1515/prolas-2016-0023
M3 - Article
AN - SCOPUS:84983395537
SN - 1407-009X
VL - 70
SP - 175
EP - 181
JO - Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
JF - Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
IS - 4
ER -